Participants' global self‐assessment of acne improvement Good to excellent improvement (medium term: treatment duration from 5 to 8 weeks) · participants with acne
It is very uncertain whether salicylic acid changes participants' global self‐assessment of acne improvement Good to… compared with pyruvic acid (very low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · participants with acne
Salicylic acid showed no clear difference in withdrawal for any reason (medium term: treatment duration from 5 to… compared with pyruvic acid (low certainty).
1 finding from 1 review
Minor adverse events · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
1 finding from 1 review
Participants' global self‐assessment of acne improvement · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · participants with acne
1 finding from 1 review
Minor adverse events · participants with acne
It is very uncertain whether salicylic acid changes total number of participants who experienced at least one minor… compared with benzoyl peroxide (very low certainty).
1 finding from 1 review
Quality of life (change from baseline) in the medium term · participants with acne
1 finding from 1 review
Participants' global self‐assessment of acne improvement Moderate to excellent improvement (long term: treatment duration > 8 weeks) · participants with acne
Salicylic acid showed no clear difference in participants' global self‐assessment of acne improvement Moderate to… compared with tretinoin (low certainty).
1 finding from 1 review
Treatment withdrawal · participants with acne
1 finding from 1 review
Minor adverse events · participants with acne
It is very uncertain whether salicylic acid changes total number of participants who experienced at least one minor… compared with tretinoin (very low certainty).
1 finding from 1 review
Quality of life AQOL (long term: treatment duration > 8 weeks) · participants with acne
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found